Fosamax Osteonecrosis of the Jaw Settlement: Criteria Explained

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Education to Specialized Risk Assessment

The legacy of general health and science information has long served as a foundation for public understanding of medical conditions and treatment options. Within this broad context, discussions of bone health and the management of osteoporosis have been prominent, with bisphosphonate therapies such as Fosamax (alendronate) frequently highlighted for their efficacy in reducing fracture risk. This general health framework has provided patients and healthcare providers with essential knowledge about maintaining skeletal integrity and the pharmacological tools available to achieve that goal. As this informational heritage evolves, a more focused concern has emerged regarding the specific risks associated with prolonged bisphosphonate exposure. Among these, the potential for osteonecrosis of the jaw (ONJ) has become a significant topic of clinical and legal attention. This condition, characterized by exposed necrotic bone in the maxillofacial region, has been linked to long-term use of medications like Fosamax, particularly in patients undergoing dental procedures or with other risk factors. The transition from general health education to this specialized concern requires careful consideration of exposure duration, dosage, and individual patient susceptibility.

Clinical Presentation and Diagnosis of Osteonecrosis of the Jaw

Osteonecrosis of the jaw presents as exposed bone in the oral cavity that persists for more than eight weeks, often with associated pain, swelling, and infection. The condition can occur spontaneously but is generally associated with tooth extraction or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Diagnosis is primarily clinical, based on visual examination and patient history, and may be supported by imaging studies. The time to onset of symptoms after starting Fosamax can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients experience relief of symptoms after discontinuing the drug, though a subset may have recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Fosamax Pharmacology and Mechanistic Pathways

Fosamax (alendronate) works by inhibiting osteoclast-mediated bone resorption, which reduces bone turnover. This mechanism is beneficial for treating osteoporosis but may contribute to ONJ development. The jawbone has unique structural and metabolic characteristics that may predispose it to bisphosphonate-related complications. A multiscale characterization of jawbone in estrogen-deficient rats treated with alendronate found that most jawbone characteristics were not significantly different from sham controls, but the surface of alveolar bone surrounding teeth showed a trend of more erosion and addition of new bone tissues in ovariectomized rat groups (https://pubmed.ncbi.nlm.nih.gov/40345077/). This suggests that bisphosphonate treatment may alter local bone remodeling dynamics in the jaw, potentially increasing susceptibility to ONJ. The same study noted that treatments using alendronate did not substantially change jawbone characteristics in ovariectomized rats, which differed from findings in lumbar vertebrae (https://pubmed.ncbi.nlm.nih.gov/40345077/). This indicates that the jawbone may respond differently to bisphosphonate therapy compared to other skeletal sites, highlighting the need for site-specific risk assessment.

Risk Factors and Adequacy of Warnings

Known risk factors for ONJ in patients taking bisphosphonates, including Fosamax, include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The prescribing information for Fosamax includes warnings about ONJ, noting that it has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, the adequacy of these warnings in informing patients and healthcare providers about the full scope of risk, particularly regarding the timeline between exposure and harm, remains a subject of legal scrutiny.

Timeline Between Exposure and Documented Harm

The time to onset of ONJ symptoms after starting Fosamax can range from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This variability complicates the establishment of a clear causal link in individual cases. The condition is generally associated with dental procedures or local infections, which may act as precipitating events in patients already on bisphosphonate therapy (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The risk may increase with longer duration of exposure, but ONJ can occur after short-term use as well.

Settlement-Related Considerations for Affected Patients

For patients who have developed ONJ after using Fosamax, settlement considerations typically involve demonstrating that the drug caused or contributed to the condition, and that the manufacturer failed to provide adequate warnings. Key factors in evaluating claims include the timing of symptoms relative to drug initiation, the presence of known risk factors, and whether the patient underwent dental procedures during treatment. The evidence indicates that discontinuation of bisphosphonate treatment may reduce the risk of ONJ in patients requiring invasive dental procedures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Patients should consult with legal counsel to assess their individual circumstances and the applicability of settlement criteria.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is osteonecrosis of the jaw (ONJ) and how is it related to Fosamax?

Osteonecrosis of the jaw is a condition characterized by exposed, non-healing bone in the jaw, often associated with bisphosphonate medications like Fosamax. It can occur spontaneously or after dental procedures, and symptoms may appear from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures, cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids), poor oral hygiene, periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures. The risk may increase with longer duration of bisphosphonate use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

How is ONJ diagnosed and what is the typical timeline for symptoms?

Diagnosis is primarily clinical, based on visual examination and patient history, with imaging support. Symptoms can appear from one day to several months after starting Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What settlement criteria are considered for Fosamax-related ONJ claims?

Settlement criteria typically require demonstrating that Fosamax caused or contributed to ONJ and that the manufacturer failed to provide adequate warnings. Key factors include timing of symptoms, presence of risk factors, and dental procedures during treatment. Discontinuation of bisphosphonate may reduce risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.